Report · S7681
FDA OCET Overview of the BAA — selected contract metadata, December 6, 2022
Robert Orr’s FDA presentation publicly describes a 2017 modification of contract HHSF223201610018C and links 75F40120C00176 to a collaboration studying COVID-19 illness in diverse populations. These identifiers match contracts acknowledged for Nolan in MaxFuse. The slides document agency statements about public research funding; they do not name Nolan or establish secret invitations or UAP access.
Read the document at fda.govWhat we checked
Root received/hash-verified original 13-leaf FDA PDF and read native extracted leaves 1,4,7,10. One selected native layout actually viewed; full document graphics/layouts and executed agreements/modifications remain unreviewed. All available web-extracted text read, without complete native graphical meaning or verified live delivery.
Partial root native PDF text and selected layout review
How we check sources
Not checked yet
- Full parent native layouts/graphics and complete illustrated document remain unreviewed; one selected layout viewed.
- Original executed contracts, modifications, task statements and current obligations/payment history not reviewed.
- Institution/project support is not a named Nolan principal-investigator finding, personal payment or classified UAP approach.
- Same contract has differing award-table and later presentation descriptions; original amendment/naming history remains unknown.
- Published and file metadata dates remain distinct. No operational study/protocol, patient records or claimed personal briefing reviewed.
Cite this record
Robert Orr, U.S. Food and Drug Administration. FDA OCET Overview of the BAA — selected contract metadata, December 6, 2022. December 6, 2022. BioParity S7681. https://bioparity.io/sources/S7681Record data (JSON)